Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06667700 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
A Phase 3 study of Coronavirus Disease (COVID-19), sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 3,082
- Enrollment target
- 20
- Study locations
NCT06667700: Recruiting Phase 3 study of Coronavirus Disease (COVID-19), sponsored by Merck Sharp & Dohme.
NCT06667700 is a Phase 3 study of Coronavirus Disease (COVID-19) that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 3,082 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (299% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06667700, a Phase 3 study of Coronavirus Disease (COVID-19), is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 3,082 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symptoms. However, people with certain health conditions or other factors have a high risk (chance) of getting severely ill from COVID-19, which can require a hospital stay or lead to death. Some people who are high risk for severe illness may be unable to take certain treatments for COVID-19 because they are not available to them, or they take other medicines that may react with a treatment and cause an unwanted effect. Molnupiravir (MK-4482) is a study medicine designed to stop the COVID-19 virus from copying itself in the body (multiplying). The goal of this study is to learn if molnupiravir prevents severe illness from COVID-19 more than placebo in people who are high risk.
Primary Outcome
Hospitalization is defined as ≥24 hours of acute care in a hospital or similar acute care facility, including emergency rooms or facilities created to address hospitalization needs specifically for COVID-19. Hospitalization and death may be due to any cause. An MAV is defined as any unscheduled, nonroutine healthcare visit where the participant is evaluated by a licensed (according to local/national guidelines) healthcare provider. As prespecified by the protocol, the percentage of participants
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Molnupiravir
Study Locations (20)
California
- Clinica de Salud del Valle de Salinas ( Site 3825) - Castroville
- Ascada Health PC dba Ascada Research ( Site 3750) - Fullerton
- Pacific Clinical Studies ( Site 3827) - Los Alamitos
- Valley Clinical Trials, Inc. ( Site 3707) - Northridge
- FOMAT Medical Research ( Site 3720) - Oxnard
- Paradigm Clinical Research, LLC ( Site 3785) - San Diego
- Optimus Medical ( Site 3817) - San Francisco
- Millennium Clinical Trials ( Site 3758) - Westlake Village
Florida
- Encore Medical Research of Boynton Beach ( Site 3701) - Boynton Beach
- Prestige Clinical Research Center ( Site 3722) - Coral Gables
- Indago Research & Health Center, Inc ( Site 3714) - Hialeah
- Prestige Clinical Research ( Site 3830) - Homestead
- Accel Research Sites Network - St. Pete-Largo Clinical Research Unit ( Site 3779) - Largo
- Clinical Site Partners, LLC dba Flourish Research ( Site 3717) - Leesburg
- Advanced Pulmonary Research Institute ( Site 3781) - Loxahatchee Groves
- Southern Clinical Research ( Site 3773) - Miami
Arizona
- Helios Clinical Research ( Site 3826) - Paradise Valley
- Absolute Clinical Research ( Site 3709) - Phoenix
Alabama
- Cullman Clinical Trials ( Site 3813) - Cullman
Colorado
- Paradigm Clinical Research Centers, Inc ( Site 3718) - Wheat Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,082 participants |
| Start Date | 2024-12-02 |
| Est. Completion | 2031-01-26 |
| Phase | Phase 3 |
What NCT06667700 shows while recruiting
NCT06667700 is an interventional study that assigns participants to a tested intervention. Its 3,082 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (299% higher).
The record links to 1 condition, with Coronavirus Disease (COVID-19) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06667700 names 20 study sites across 5 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06667700 about?
NCT06667700 is a clinical study titled "A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)". Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symptoms. However, people with certain health conditions or other factors have a high risk (chance) of getting severely ill from COVID-19, which can requir...
What is the current status of trial NCT06667700?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 3,082 participants. The study started on 2024-12-02. Estimated completion is 2031-01-26.
What conditions does trial NCT06667700 study?
This clinical trial studies the following conditions: Coronavirus Disease (COVID-19).
What interventions are being tested in trial NCT06667700?
The interventions under investigation include: Placebo (DRUG), Molnupiravir (DRUG).
Who is sponsoring clinical trial NCT06667700?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06667700 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06667700's enrollment target sits among peer trials
3,082 76th of 2000 higher than 1,925 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05534243 · 3,090 participants · NA
The ED-AWARENESS-2 Trial
- NCT04722822 · 3,100 participants · NA
The HPV 9-10 Trial: Early Initiation of HPV Vaccination
- NCT05051722 · 3,110 participants
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- NCT07116967 · 3,040 participants · Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI